Another variation of the theme shown in Figure 1A was to combine the ICD-inducing chemo agent, mitoxantrone, with a cholesterol-conjugated inhibitor of the indoleamine-pyrrole 2,3-dioxygenase (IDO-1) pathway, indoximod, in bilayer carriers for the treatment of triple-negative breast cancer, colon, and lung cancer [21]. This evidence concerns the gene IDO1 and triple-negative breast carcinoma.